A push to administer thousands of COVID-19 vaccines before they expire has shortened the recommended dosing interval for some Ontarians, but one expert says that any difference in protection is likely negligible.
The province announced last week that the first cohort of Ontarians who received the Oxford-AstraZeneca shot in March were now eligible to schedule second jabs — marking 10 weeks from their first shot.
A recent study out of the United Kingdom found that lengthening AstraZeneca’s dosing interval to 12 weeks or more was more effective against COVID-19 than administering the doses six weeks apart.
The findings seemed to back Canada’s recommended strategy to delay second doses in order to administer more first doses. Health Canada says the gap between shots can stretch 4 to 12 weeks, while the National Advisory Committee on Immunization has recommended an extended interval of up to 16 weeks.
Early 2nd shot won’t impact effectiveness, expert says
Dr. Allison McGeer, a professor in laboratory medicine and pathobiology at the University of Toronto, says taking a second vaccine dose at 10 weeks instead of 12 likely won’t impact its effectiveness.
“I can tell you that 12 weeks is better than four weeks, but I can’t tell you whether … 12 weeks is better than 10,” McGeer said during an Ontario Medical Association virtual press briefing on Wednesday.
“[But] personally, from my experience with vaccines, I’m with the province on this one.
“I do not think that your [immune] response is going to be different at 10 weeks than it is at 12 weeks.”
While some early AstraZeneca recipients may be wondering if they’re getting shortchanged by getting a second dose earlier, McGeer said vaccine schedules are typically “invented.”
“We decide what we think will work, and then we try it out and if it works we say, ‘Great,’ and we move on,” she said. “We don’t spend a lot of time saying: ‘Well, if we vaccinate you at 10 weeks or 12 weeks or 14 weeks or six weeks, is that a little bit better?”‘
Ontario administered nearly one million doses of the AstraZeneca vaccine before halting first shots earlier this month due to what it said was an increased risk of blood clots.
The jab has been associated with vaccine-induced immune thrombotic thrombocytopenia (VITT), an extremely rare blood clotting condition that while treatable, can also be fatal.
The chances of acquiring VITT from a second shot of AstraZeneca are believed to be more rare than with the first dose, though McGeer said an exact estimate of risk is still unknown.
Those who received AstraZeneca for their first dose may be eligible for an mRNA vaccine from Pfizer-BioNTech or Moderna for their second shot, but the National Advisory Committee on Immunization is still waiting for efficacy data from a U.K. trial examining that mixed-dosing strategy.
AstraZeneca doses expiring soon
McGeer said waiting for a potential mRNA dose could also put people at risk of contracting COVID-19 in the meantime because they’re not as fully protected from the virus.
“Now you’re balancing the ability to get a second dose of vaccine earlier, versus waiting for your second dose of an mRNA vaccine,” McGeer said.
Ontario has about 45,000 doses of AstraZeneca expiring Monday, and pharmacies are aiming to dispense them within the next few days to avoid wastage. Another 10,000 doses of AstraZeneca expire next month, and the province has more than 300,000 doses in stock.
Dr. Zain Chagla, an infectious disease expert in Hamilton, says that with a steady, increased supply of mRNA vaccines coming in, it may be time for Canada to re-assess the amount of doses it needs right now.
He says some future shipments could be more useful in other countries that don’t have equitable access to the same inoculations.
“Does that mean we don’t vaccinate our population? No … but we do have to make difficult decisions about what the next three months of our vaccine plan looks like,” Chagla said.
“Where do we set the cutoff to say: ‘OK, we’re not going to accept any more AstraZeneca into Canada … where is the cut off for Johnson & Johnson?’
“Do we need this as part of our vaccine strategy or can we give that back to the world?”